What Generate Biomedicines, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 12 |
| Sells | 1 | 1 |
| Total trades | 1 | 25 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 76,719,605 |
| Disposed | 1,000 | 1,000 |
| Net activity | −1,000 | +76,718,605 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Arnold Frances | Director | Sep 01 | Open-market sale · S | −1,000 | $16.00 | −$16K | 231,472 |
| Nally Michael | Chief Executive Officer | Mar 04 | Open-market buy · P | +20,000 | $12.00 | +$240K | 572,707 |
| Silvers Jason | President & CFO | Mar 02 | Open-market buy · P | +1,000 | $16.00 | +$16K | 1,000 |
| Silvers Jason | President & CFO | Mar 02 | Open-market buy · P | +500 | $16.00 | +$8K | 500 |
| Silvers Jason | President & CFO | Mar 02 | Open-market buy · P | +500 | $16.00 | +$8K | 500 |
| Grous Beth | Chief People Officer | Mar 02 | Open-market buy · P | +300 | $16.00 | +$4.8K | 300 |
| Afeyan Noubar | Director | Mar 02 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 1,562,500 |
| Afeyan Noubar | Director | Mar 02 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 4,340,252 |
| Afeyan Noubar | Director | Mar 02 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 15,264,724 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +2,777,752 | — | — | 2,777,752 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +2,777,752 | — | — | 2,777,752 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +987,491 | — | — | 987,491 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +13,702,224 | — | — | 13,702,224 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +12,723,940 | — | — | 12,723,940 |
| Afeyan Noubar | Director | Mar 02 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 1,562,500 |
| Afeyan Noubar | Director | Mar 02 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 4,340,252 |
| Afeyan Noubar | Director | Mar 02 | Open-market buy · P | +1,562,500 | $16.00 | +$25M | 15,264,724 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +2,777,752 | — | — | 2,777,752 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +2,777,752 | — | — | 2,777,752 |
| Afeyan Noubar | Director | Mar 02 | Derivative Conversion · C | +987,491 | — | — | 987,491 |
Loading...